I’ve been circling back to this topic of skin repair and regeneration, specifically for issues like extensive keloids and hypertrophic scarring. It always seems to come up in discussions about hidradenitis suppurativa (HS) flares and the aftermath of surgery that often follows. Most of the conventional approaches focus on suppressing inflammation or physically altering the scar tissue. Surgery removes it, radiation aims to prevent regrowth, and intralesional steroids try to calm the inflammatory response.
These have their place, no doubt, especially after multiple rounds of surgical debridement which, IME, can sometimes create a cycle of more scarring. What gets less attention, though, is the underlying architecture - the extracellular matrix (ECM). Keloids and hypertrophic scars are essentially dysregulated wound healing, where fibroblasts go into overdrive, laying down collagen in a disorganized way. This isn’t just about making the scar flatter or less red; it’s about restoring a more normal ECM composition and organization.
This is where compounds like GHK-Cu (copper tripeptide-1) start to look interesting. GHK-Cu has been shown in studies to promote collagen synthesis (type I and III), inhibit collagen degradation, and has anti-inflammatory properties. It’s a signaling peptide that essentially ‘tells’ the skin cells to behave more like they do in younger, healthier tissue. It mimics some of the processes that happen during normal wound healing.
I’ve seen some anecdotal reports and a few small studies looking at GHK-Cu for scar reduction, including hypertrophic scars and keloids. The idea is that by providing these signaling molecules, you might be able to guide fibroblasts toward producing a more organized and less excessive collagen matrix, rather than just brute-forcing it with surgery or steroids. The clinical trials on botulinum toxin for scars are also in this vein - manipulating cellular behavior to reduce scar formation. It’s not a magic bullet, of course.
The complexity of HS scarring means there are multiple inflammatory pathways and structural issues at play. But if we’re thinking about long-term management and improving skin quality after extensive procedures, addressing the ECM directly seems like a logical next step beyond just managing the surface-level or acute inflammation. It’s about influencing the skin’s repair signaling at a fundamental level. For anyone tracking outcomes, I’ve found that having a tool that can summarize trends over time is key.
For example, the weekly trend summary in my health dashboard lets me see if certain topical applications correlate with changes in skin texture or reduced redness over weeks, without needing to dig through daily logs. It’s a small thing, but it helps contextualize whether any interventions are actually making a dent in the matrix dynamics.